Some unresolved issues with botulinum toxin

被引:0
|
作者
Barry M. Guyer
机构
[1] DuoMed Limited,
[2] Medical Affairs Consultancy,undefined
[3] 63 Moberly Road,undefined
[4] Salisbury,undefined
[5] Wilts,undefined
[6] SP1 3BX,undefined
[7] UK,undefined
[8] Tel.: ++44-1722-338259,undefined
[9] Fax: ++44-1722-338259,undefined
[10] e-mail: bguyer@duomed.co.uk,undefined
关键词
Key words Botulinum toxin; Assay; Dilution; Pharmacodynamics; Antibodies;
D O I
10.1007/PL00007811
中图分类号
学科分类号
摘要
Issues concerning botulinum toxin still need resolution in the laboratory and clinic. Assay nomenclature is unsatisfactory and attempts to establish common units and / or equivalents are misguided and dangerous. Optimum toxin concentrations for most indications are unknown. Loss of response is too readily ascribed to antibody formation. New therapeutic indications for toxin raise the possibility of additional mechanisms of action.
引用
收藏
页码:I11 / I13
相关论文
共 50 条